A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir

A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir

A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infectious Diseases 2022-11, Vol.9 (11), p.ofac550
Hauptverfasser: Ramirez-Sanchez, Claudia, Kozuch, Jade, Shah, Mita M, Berumen, Jennifer, Mekeel, Kristin, Schnickel, Gabriel, Taremi, Mahnaz, Golts, Eugene, Afshar, Kamyar, Adler, Eric, Pretorius, Victor, Aslam, Saima
Format: Artikel
Sprache:eng
Schlagworte:
Antithymocyte globulin
Atazanavir
Brief Report
Clinical trials
Health aspects
Hepatitis C virus
Infection
Prevention
Transplantation of organs, tissues, etc
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofac550